phase readout
saveNCT04088409: A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
ACTIVE_NOT_RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Eli Lilly and Company. Phase: PHASE3. Conditions: Uveitis
view source ↗
comments(0)
5-min edit window · permanent after that